{"organizations": [], "uuid": "f1528d5d70967cf0fa7506190325595c4fb43677", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-amicus-announces-additional-data-i/brief-amicus-announces-additional-data-in-pompe-disease-phase-1-2-study-idUSFWN1PX1KF", "country": "US", "domain_rank": 408, "title": "BRIEF-Amicus Announces Additional Data In Pompe Disease Phase 1/2 Study", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-02-07T23:39:00.000+02:00", "replies_count": 0, "uuid": "f1528d5d70967cf0fa7506190325595c4fb43677"}, "author": "", "url": "https://www.reuters.com/article/brief-amicus-announces-additional-data-i/brief-amicus-announces-additional-data-in-pompe-disease-phase-1-2-study-idUSFWN1PX1KF", "ord_in_thread": 0, "title": "BRIEF-Amicus Announces Additional Data In Pompe Disease Phase 1/2 Study", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "study reuters staff", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}, {"name": "amicus therapeutics inc", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "February 7, 2018 / 9:40 PM / Updated 3 minutes ago BRIEF-Amicus Announces Additional Data In Pompe Disease Phase 1/2 Study Reuters Staff 1 Min Read \nFeb 7 (Reuters) - Amicus Therapeutics Inc: \n* AMICUS THERAPEUTICS ANNOUNCES ADDITIONAL POSITIVE DATA IN POMPE DISEASE PHASE 1/2 STUDY AT 14TH ANNUAL WORLDSYMPOSIUMâ„¢ \n* AMICUS THERAPEUTICS INC - CONSISTENT AND DURABLE RESPONSES ACROSS KEY MEASURES OF SAFETY, FUNCTIONAL OUTCOMES AND BIOMARKERS OUT TO MONTH 12 IN TRIAL \n* AMICUS THERAPEUTICS INC - VERY LOW RATE (<1%) OF INFUSION ASSOCIATED REACTIONS MAINTAINED AFTER 550+ INFUSIONS IN TRIAL Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-02-07T23:39:00.000+02:00", "crawled": "2018-02-07T23:50:24.016+02:00", "highlightTitle": ""}